nach oben

Erschienen in:

01.08.2012 | Original Research Paper

Local and systemic pro-inflammatory and anti-inflammatory cytokine patterns in patients with chronic subdural hematoma: a prospective study

verfasst von: Milo Stanisic, Ansgar Oddne Aasen, Are Hugo Pripp, Karl-Fredrik Lindegaard, Jon Ramm-Pettersen, Staale Petter Lyngstadaas, Jugoslav Ivanovic, Ane Konglund, Eivind Ilstad, Tiril Sandell, Omar Ellingsen, Terje Sæhle

Erschienen in: Inflammation Research | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective and design

Innate immune pro- and anti-inflammatory responses in patients with chronic subdural hematoma (CSDH) were investigated by measuring and comparing the systemic and subdural fluid levels of cytokines.

Materials and method

Cytokine values were analyzed in samples obtained during surgery of 56 adult patients who were operated on for unilateral CSDHs using a Multiplex antibody bead kit.

Results

There were significantly higher levels of the pro-inflammatory IL-2R (p = 0.004), IL-5 (p < 0.001), IL-6 (p < 0.001), and IL-7 (p < 0.001), and anti-inflammatory mediators IL-10 (p < 0.001) and IL-13 (p = 0.002) in CSDH fluid compared with systemic levels. The pro-inflammatory TNF-alpha (p < 0.001), IL-1beta (p < 0.001), IL-2 (p = 0.007) and IL-4 (p < 0.001) were significantly lower in hematoma fluid compared with systemic levels. The ratios between pro- versus anti-inflammatory cytokines were statistically significant higher in CSDH (7.8) compared with systemic levels (1.3).

Conclusions

The innate immune responses occur both locally at the site of CSDH, as well as systematically in patients with CSDH. The local hyper-inflammatory and low anti-inflammatory responses exist simultaneously. The findings suggest poorly coordinated innate immune responses at the site of CSDH that may lead to propagating of local inflammatory process and basically contribute to formation and progression of CSDH.

Chen JC, Levy ML. Causes, epidemiology, and risk factors of chronic subdural hematoma. Neurosurg Clin North Am. 2000;11:399–406.

Weigel R, Schmiedek P, Krauss JK. Outcome of contemporary surgery for chronic subdural haematoma: evidence based review. J Neurol Neurosurg Psychiatry. 2003;74:937–43.PubMedCrossRef

DE Haines, Harkey HL, al-Mefty O. The “subdural” space: a new look at an outdated concept. Neurosurgery. 1993;32:111–20.PubMedCrossRef

Mack J, Squier W, Eastman JT. Anatomy and development of the meninges: implications for subdural collections and CSF circulation. Pediatr Radiol. 2009;39:200–10.PubMedCrossRef

Reina MA, Casasola ODL, Lopez A, De Andres JA, Mora M, Fernandez A. The origin of the spinal subdural space: ultrastructure findings. Anesth Analg. 2002;94:991–5.PubMedCrossRef

Frati A, Salvati M, Mainiero F, Ippoliti F, Rocchi G, Raco A, Caroli E, Cantore G, Delfini R. Inflammation markers and risk factors for recurrence in 35 patients with a posttraumatic chronic subdural hematoma: a prospective study. J Neurosurg. 2004;100:24–32.PubMed

Hirashima Y, Endo S, Kato R, Ohmori T, Nagahori T, Nishijima M, Karasawa K, Nojima S, Takaku A. Platelet-activating factor (PAF) and the development of chronic subdural haematoma. Acta Neurochir (Wien). 1994;129:20–5.CrossRef

Hong HJ, Kim YJ, Yi HJ, Ko Y, Oh SJ, Kim JM. Role of angiogenic growth factors and inflammatory cytokine on recurrence of chronic subdural hematoma. Surg Neurol. 2009;71:161–6.PubMedCrossRef

Suzuki M, Endo S, Inada K, Kudo A, Kitakami A, Kuroda K, Ogawa A. Inflammatory cytokines locally elevated in chronic subdural haematoma. Acta Neurochir (Wien). 1998;140:51–5.CrossRef

10.

Wada T, Kuroda K, Yoshida Y. Local elevation of the anti-inflammatory interleukin-10 in the pathogenesis of chronic subdural hematoma. Neurosurg Rev. 2006;29:242–5.PubMedCrossRef

11.

Hohenstein A, Erber R, Schilling L, Weigel R. Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA within the neomembranes of chronic subdural hematoma. J Neurotrauma. 2005;22:518–28.PubMedCrossRef

12.

Katano H, Kamiya K, Mase M, Tanikawa M, Yamada K. Tissue plasminogen activator in chronic subdural hematomas as a predictor of recurrence. J Neurosurg. 2006;104:79–84.PubMedCrossRef

13.

Nanko N, Tanikawa M, Mase M, Fujita M, Tateyama H, Miyati T, Yamada K. Involvement of hypoxia-inducible factor-1α and vascular endothelial growth factor in the mechanism of development of chronic subdural hematoma. Neurol Med Chir (Tokyo). 2009;49:379–85.CrossRef

14.

Shono T, Inamura T, Morioka T, Matsumoto K, Suzuki SO, Ikezaki K, Iwaki T, Fukui M. Vascular endothelial growth factor in chronic subdural haematomas. J Clin Neurosci. 2001;8:411–5.PubMedCrossRef

15.

Suzuki K, Takano S, Nose T, Doi M, Ohasi N. Increased concentration of vascular endothelial growth factor (VEGF) in chronic subdural hematoma. J Trauma. 1999;46:532–3. (Letter).PubMedCrossRef

16.

Vaquero J, Zurita M, Cincu R. Vascular endothelial growth-permeability factor in granulation tissue of chronic subdural haematomas. Acta Neurochir (Wien). 2002;144:343–7.CrossRef

17.

Weigel R, Schilling L, Schmiedek P. Specific pattern of growth factor distribution in chronic subdural hematoma (CSH): evidence for an angiogenic disease. Acta Neurochir (Wien). 2001;143:811–9.CrossRef

18.

Friede RL, Schachenmayer W. The origin of subdural neomembranes II. Fine structure of neomembranes. Am J Pathol. 1978;92:69–84.PubMed

19.

Moskala M, Gościński I, Kałuża J, Polar J, Krupa M, Adamek D, Pityński K, Miodoński AJ. Morphological aspects of the traumatic chronic subdural hematoma capsule: SEM studies. Microsc Microanal. 2007;13:211–9.PubMedCrossRef

20.

Yamashima T, Yamamoto S. The origin of inner membranes in chronic subdural hematomas. Acta Neuropathol. 1985;67:219–25.PubMedCrossRef

21.

Fujisawa H, Ito H, Kashiwagi S, Nomura S, Toyosawa M. Kallikrein-kinin system in chronic subdural haematomas: Its role in vascular permeability and regulation of fibrinolysis and coagulation. J Neurol Neurosurg Psychiatry. 1995;59:388–94.PubMedCrossRef

22.

Murakami H, Hirose Y, Sagoh M, Shimizu K, Kojima M, Gotoh K, Mine Y, Hayashi T, Kawase T. Why do chronic subdural hematomas continue to grow slowly and not coagulate? Role of thrombomodulin in the mechanism. J Neurosurg. 2002;96:877–84.PubMedCrossRef

23.

Nomura S, Kashiwagi S, Fujisawa H, Ito H, Nakamura K. Characterization of local hyperfibrinolysis in chronic subdural hematomas by SDS-PAGE and immunoblot. J Neurosurg. 1994;81:910–3.PubMedCrossRef

24.

Suzuki M, Kudo A, Kitakami A, Doi M, Kubo N, Kuroda K, Ogawa A. Local hypercoagulative activity precedes hyperfibrinolytic activity in the subdural space during development of chronic subdural haematoma from subdural effusion. Acta Neurochir (Wien). 1998;140:261–6.CrossRef

25.

Weir B, Gordon P. Factors affecting coagulation: fibrinolysis in chronic subdural fluid collection. J Neurosurg. 1983;58:242–5.PubMedCrossRef

26.

Kawano N, Suzuki K. Presence of smooth-muscle cells in the subdural neomembrane. J Neurosurg. 1981;54:646–51.PubMedCrossRef

27.

Sarkar C, Lakhtakia R, Gill SS, Sharma MC, Mahapatra AK, Mehta VS. Chronic subdural haematoma and the enigmatic eosinophil. Acta Neurochir (Wien). 2002;144:983–8.CrossRef

28.

Dinarello CA. Proinflammatory cytokines. Chest. 2000;118:503–8.PubMedCrossRef

29.

Li H, Lin X. Positive and negative signalling components involved in TNF-alpha-induced NF-kappaB activation. Cytokine. 2008;41:1–8.PubMedCrossRef

30.

Apte SH, Baz A, Kelso A, Kienzle N. Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells. Proc Natl Acad Sci USA. 2008;105:17475–80.PubMedCrossRef

31.

Arai K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem. 1990;59:783–836.PubMedCrossRef

32.

Boyman O, Ramsey C, Kim DM, Sprent J, Surh CD. Il-7/Anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol. 2008;180:7265–75.PubMed

33.

Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99:3892–904.PubMedCrossRef

34.

Nelson BH, Lord JD, Greenberg PD. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature. 1994;369:333–6.PubMedCrossRef

35.

Schluns KS, Lefrançois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3:269–79.PubMedCrossRef

36.

Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595–601.PubMedCrossRef

37.

Dubucquoi S, Desreumaux P, Janin A, Klein O, Goldman M, Tavernier J, Capron A, Capron M. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med. 1994;179:703–8.PubMedCrossRef

38.

Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78.PubMedCrossRef

39.

Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253–78.PubMedCrossRef

40.

Maruo N, Morita I, Shirao M, Murota S-I. IL-6 increases endothelial permeability in vitro. Endocrinology. 1992;131:710–4.PubMedCrossRef

41.

Strazynski M, Eble JA, Kresse H, Schönherr E. Interleukin (IL)-6 and IL-10 induce decorin mRNA in endothelial cells, but interaction with fibrillar collagen is essential for its translation. J Biol Chem. 2004;279:21266–70.PubMedCrossRef

42.

Tilg H, Trehu E, Atkins MB. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113–8.PubMed

43.

Trinchieri G. Interleukin-12 a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. J Immunol. 1995;13:251–76.CrossRef

44.

Numasaki M, Fukushi JI, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101:2620–7.PubMedCrossRef

45.

Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133–41.PubMedCrossRef

46.

Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27–55.PubMedCrossRef

47.

Moore KW, O’Gara A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol. 1993;11:165–90.PubMedCrossRef

48.

Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.PubMedCrossRef

49.

Moore KW, de Waal MR, Coffman RI, O’Gara A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.PubMedCrossRef

50.

Seymour RM, Henderson B. Pro-inflammatory-anti-inflammatory cytokine dynamics mediated by cytokine-receptor dynamics in monocytes. IMA J Math Appl Med. 2001;18:159–92.CrossRef

51.

Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425–56.PubMedCrossRef

52.

Minty A, Chalon P, Derocq JM, Dumont X, Guillemont JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Schire D, Ferrara P, Caput D. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248–50.PubMedCrossRef

53.

Schlag G, Redl H. Mediators of injury and inflammation. World J Surg. 1996;20:406–10.PubMedCrossRef

54.

Stahel PF, Morganti-Kossmann MC, Kossmann T. The role of the complement system in traumatic brain injury. Brain Res Rev. 1998;27:243–56.PubMedCrossRef

55.

Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36:691–709.PubMedCrossRef

56.

Schmidt OI, Heyde CE, Ertel W, Stahel PF. Closed head injury-an inflammatory disease? Brain Res Rev. 2005;48:388–99.PubMedCrossRef

57.

Liew FY, McInnes IB. The role of innate mediators in inflammatory response. Mol Immunol. 2002;38:887–90.PubMedCrossRef

58.

McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol. 2004;4:392–7.PubMedCrossRef

Titel: Local and systemic pro-inflammatory and anti-inflammatory cytokine patterns in patients with chronic subdural hematoma: a prospective study
verfasst von: Milo Stanisic
Ansgar Oddne Aasen
Are Hugo Pripp
Karl-Fredrik Lindegaard
Jon Ramm-Pettersen
Staale Petter Lyngstadaas
Jugoslav Ivanovic
Ane Konglund
Eivind Ilstad
Tiril Sandell
Omar Ellingsen
Terje Sæhle
Publikationsdatum: 01.08.2012
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 8/2012
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-012-0476-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective and design

Materials and method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2012

Inflammatory markers and bariatric surgery: a meta-analysis

Use of blood urea nitrogen, creatinine, interleukin-6, granulocyte–macrophage colony stimulating factor in combination to predict the severity and outcome of abdominal sepsis in rats

Carrageenan-induced transient inflammation in a rabbit knee model: molecular changes consistent with an early osteoarthritis phenotype

Anti-inflammatory effects of arbutin in lipopolysaccharide-stimulated BV2 microglial cells

Association of promoter region single nucleotide polymorphisms at positions −819C/T and −592C/A of interleukin 10 gene with ischemic heart disease